Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.
Standard
Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation. / Langebrake, Claudia; Bernhardt, Friederike; Baehr, Michael; Kröger, Nicolaus; Zander, Axel R.
In: INT J CLIN PHARM-NET, Vol. 33, No. 6, 6, 2011, p. 918-924.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.
AU - Langebrake, Claudia
AU - Bernhardt, Friederike
AU - Baehr, Michael
AU - Kröger, Nicolaus
AU - Zander, Axel R.
PY - 2011
Y1 - 2011
N2 - The effects of physiological changes in patients with obesity on pharmacokinetic parameters and the time course of drug response, especially in the field of haematology/oncology, are poorly understood. For some antimicrobial drugs, dosing considerations exist, while for cytostatic drugs, dose modifications for obese patients are not consistently recommended. Glomerular filtration rate and renal perfusion appear to be similar in obese and normal weight individuals, thus elimination of hydrophilic and extensively renally cleared drugs mainly depends upon creatinine clearance.
AB - The effects of physiological changes in patients with obesity on pharmacokinetic parameters and the time course of drug response, especially in the field of haematology/oncology, are poorly understood. For some antimicrobial drugs, dosing considerations exist, while for cytostatic drugs, dose modifications for obese patients are not consistently recommended. Glomerular filtration rate and renal perfusion appear to be similar in obese and normal weight individuals, thus elimination of hydrophilic and extensively renally cleared drugs mainly depends upon creatinine clearance.
M3 - SCORING: Journal article
VL - 33
SP - 918
EP - 924
JO - INT J CLIN PHARM-NET
JF - INT J CLIN PHARM-NET
SN - 2210-7703
IS - 6
M1 - 6
ER -